Nanoformulations of Anticancer FGFR Inhibitors with Improved Therapeutic Index

Fibroblast growth factor receptor (FGFR) inhibitors like ponatinib and nintedanib are clinically approved for defined cancer patient cohorts but often exert dose-limiting adverse effects. Hence, we encapsulated FGFR inhibitors ponatinib, PD173074, and nintedanib into polylactic acid nanoparticles an...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Nanomedicine
Main Authors: Kallus, Sebastian, Englinger, Bernhard, Senkiv, Julia, Laemmerer, Anna, Heffeter, Petra, Berger, Walter, Kowol, Christian R., Keppler, Bernhard K.
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611408/
https://ncbi.nlm.nih.gov/pubmed/30121385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nano.2018.08.001
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares